Patents by Inventor Ruediger Ridder
Ruediger Ridder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220091122Abstract: The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids.Type: ApplicationFiled: May 10, 2021Publication date: March 24, 2022Inventors: Magnus Von Knebel-Doeberitz, Johannes Gebert, Michael Linnebacher, Stefan Woerner, Ruediger Ridder, Peer Bork, Yan Ping Yuan
-
Patent number: 11155878Abstract: The present invention relates to a method for discrimination of p16INK4a overexpressing metaplasias from neoplastic or preneoplastic p16INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16INK4a based detection of anogenital lesions in cytological testing procedures.Type: GrantFiled: February 19, 2019Date of Patent: October 26, 2021Assignee: Ventana Medical Systems, Inc.Inventors: Ruediger Ridder, Magnus Von Knebel Doeberitz, Peter Martin
-
Publication number: 20210071267Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: November 2, 2020Publication date: March 11, 2021Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20210047697Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: November 2, 2020Publication date: February 18, 2021Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Patent number: 10697966Abstract: This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.Type: GrantFiled: September 8, 2014Date of Patent: June 30, 2020Assignee: Ventana Medical Systems, Inc.Inventors: Ruediger Ridder, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz
-
Publication number: 20200017923Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: September 23, 2019Publication date: January 16, 2020Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20190265244Abstract: The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids.Type: ApplicationFiled: September 4, 2018Publication date: August 29, 2019Inventors: Magnus Von Knebel-Doeberitz, Johannes Gebert, Michael Linnebacher, Stefan Woerner, Ruediger Ridder, Peer Bork, Yan Ping Yuan
-
Publication number: 20190177804Abstract: The present invention relates to a method for discrimination of p16INK4a overexpressing metaplasias from neoplastic or preneoplastic p16INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16INK4a based detection of anogenital lesions in cytological testing procedures.Type: ApplicationFiled: February 19, 2019Publication date: June 13, 2019Inventors: Ruediger RIDDER, Magnus VON KNEBEL DOEBERITZ, Peter MARTIN
-
Patent number: 10246751Abstract: The present invention relates to a method for discrimination of p16INK4a overexpressing metaplasias from neoplastic or preneoplastic p16INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16INK4a based detection of anogenital lesions in cytological testing procedures.Type: GrantFiled: April 5, 2017Date of Patent: April 2, 2019Assignee: VENTANA MEDICAL SYSTEMS, INC.Inventors: Ruediger Ridder, Magnus Von Knebel Doeberitz, Peter Martin
-
Publication number: 20170268068Abstract: The present invention relates to a method for discrimination of p16INK4a overexpressing metaplasias from neoplastic or preneoplastic p16INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16INK4a based detection of anogenital lesions in cytological testing procedures.Type: ApplicationFiled: April 5, 2017Publication date: September 21, 2017Inventors: Ruediger RIDDER, Magnus VON KNEBEL DOEBERITZ, Peter MARTIN
-
Patent number: 9528159Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: GrantFiled: March 13, 2013Date of Patent: December 27, 2016Assignee: VENTANA MEDICAL SYSTEMS, INC.Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk, Richard Batrla
-
Patent number: 8975036Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: GrantFiled: October 29, 2008Date of Patent: March 10, 2015Assignee: Ventana Medical Systems, Inc.Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20150065383Abstract: This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.Type: ApplicationFiled: September 8, 2014Publication date: March 5, 2015Inventors: RĂ¼diger RIDDER, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz
-
Publication number: 20140363831Abstract: The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids.Type: ApplicationFiled: July 24, 2014Publication date: December 11, 2014Inventors: Magnus VON KNEBEL-DOEBERITZ, Johannes Gebert, Michael Linnebacher, Stefan Woerner, Ruediger Ridder, Peer Bork, Yan Ping Yuan
-
Patent number: 8821864Abstract: The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids.Type: GrantFiled: October 28, 2011Date of Patent: September 2, 2014Assignee: Roche MTM Laboratories AGInventors: Magnus Von Knebel-Doeberitz, Johannes Gebert, Michael Linnebacher, Stefan Woerner, Ruediger Ridder, Peer Bork, Yan Ping Yuan
-
Patent number: 8815520Abstract: The present invention relates to a method for discrimination of p16INK4a overexpressing metaplasias from neoplastic or preneoplastic p16INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16INK4a based detection of anogenital lesions in cytological testing procedures.Type: GrantFiled: August 25, 2011Date of Patent: August 26, 2014Assignee: Ventana Medical Systems, Inc.Inventors: Ruediger Ridder, Magnus Von Knebel Doeberitz, Peter Martin
-
Patent number: 8728745Abstract: The present invention concerns a method for predicting the potential for aggressive growth and/or the risk to progress to high grade cancer for tumors in cell based detection procedures. In one aspect the invention concerns the detection of overexpression of cyclin-dependent kinase inhibitor gene products as a tool for predicting the progression risk and/or potential for aggressive growth of tumors. In a second aspect the invention concerns predicting the progression risk and/or potential for aggressive growth in tumors on the basis of the simultaneous co-detection of the presence of overexpression of cyclin-dependent kinase inhibitor gene products together with the expression of markers for active cell proliferation. Further the invention concerns preparations of probes for diagnosis namely for predicting the progression risk and/or the potential for aggressive growth of tumors.Type: GrantFiled: September 4, 2009Date of Patent: May 20, 2014Assignee: Ventana Medical Sysems, Inc.Inventors: Peter Martin, RĂ¼diger Ridder
-
Patent number: 8367353Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: GrantFiled: March 6, 2009Date of Patent: February 5, 2013Assignee: Roche MTM Laboratories AGInventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20120064101Abstract: The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumours and HNPCC associated tumours. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids.Type: ApplicationFiled: October 28, 2011Publication date: March 15, 2012Inventors: Magnus Von Knebel-Doeberitz, Johannes Gebert, Michael Linnebacher, Stefan Woerner, Ruediger Ridder, Peer Bork, Yan Ping Yuan
-
Publication number: 20120052510Abstract: The present invention relates to a method for discrimination of p16INK4a overexpressing metaplasias from neoplastic or preneoplastic p16INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16INK4a based detection of anogenital lesions in cytological testing procedures.Type: ApplicationFiled: August 25, 2011Publication date: March 1, 2012Applicant: mtm Laboratories, AGInventors: Ruediger Ridder, Magnus Von Knebel Doeberitz, Peter Martin